Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma

Melanoma Research

Volumn 23, Issue 5, 2013, Pages 373-380

  Guerreschi, Pierre ^a,b   Scalbert, Camille ^a,b   Qassemyar, Ahmad ^a,b   Kluza, Jerome ^a   Ravasi, Laura ^d   Huglo, Damien ^d   Martinot Duquennoy, Veronique ^b   Formstecher, Pierre ^a   Marchetti, Philippe ^a,b,c,d   Mortier, Laurent ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b Department of Plastic Surgery ^*  (United States)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

BRAF; Metastatic melanoma; Mice model; Patient derived tumor xenograft; Rechallenge; Vemurafenib; 18F FDG PET CT

Indexed keywords

B RAF KINASE; CISPLATIN; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; KI 67 ANTIGEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMU HD; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PET SCANNER; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; MELANOMA; METABOLISM; MULTIMODAL IMAGING; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SECONDARY; SKIN NEOPLASMS; TIME;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; MELANOMA; MICE, SCID; MULTIMODAL IMAGING; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888001632     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328363ed92     Document Type: Article

References (33)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
3. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7:e35309.
4. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-3096.
5. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9:338-350.
6. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006; 66:3351-3354, discussion 4.
7. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10:1311-1316.
8. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol 2012; 30:e45-e48.
9. Benton G, Kleinman HK, George J, Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer 2011; 128:1751-1757.
10. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102:1555-1577.
11. Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, et al. Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 2012; 72:5035-5047.
12. Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, Wahl RL. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D- glucose. Cancer Res 2003; 63:6252-6257.
13. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70:5518-5527.
14. Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2012; 2:22.
15. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
16. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-977.
17. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-390.
18. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3:724-736.
19. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012; 18:33-39.
20. Smalley KSM, Sondak VK. Melanoma-an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363:876-878.
21. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-972.
22. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683-695.
23. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011; 71:5067-5074.
24. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-255.
25. Seghers AC, Wilgenhof S, Lebbe C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012; 22:466-472.
26. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17:5530-5537.
27. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011; 3:59-63.
28. Taetle R, Jones OW, Honeysett JM, Abramson I, Bradshaw C, Reid S. Use of nude mouse xenografts as preclinical screens. Characterization of xenograftderived melanoma cell lines. Cancer 1987; 60:1836-1841.
29. Han C, Shen J, Wang H, Yu L, Qian X, Liu B, et al. Personalized primary tumor xenograft model established for the pre-clinical trial to guide postoperative chemotherapy. Med Hypotheses 2012; 79:705-708.
30. Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, et al. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med 2012; 4:159-166.
31. Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010; 16:2352-2362.
32. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215.
33. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 2009; 4:1350-1362.